Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roberto Latini

Showing results (11-20 of 338) with videos related to

Pageof 34
Sort By:
European Heart Journal|October 24, 2012
What is the atrium trying to tell us?Lidia Staszewsky, Roberto Latini
JACC. Heart Failure|July 11, 2021
In Search of the Lost Ark: Will Troponin Help in Finding Effective Treatments for HFpEF?Roberto Latini, Serge Masson
Methods in Molecular Biology (Clifton, N.J.)|March 5, 2013
Myocardial infarction: cardioprotection by erythropoietinMark I Talan, Roberto Latini
Cardiovascular Drugs and Therapy|September 16, 2004
RAAS inhibitors in the cardiovascular continuum: what is still missing?Aldo P Maggioni, Roberto Latini
Blood Pressure|January 14, 2003
The angiotensin-receptor blockers: from antihypertensives to cardiovascular all-round medications in 10 years?Aldo P Maggioni, Roberto Latini
Giornale Italiano Di Cardiologia (2006)|February 3, 2026
[The paradigm shift for beta-blockers after myocardial infarction. Lessons learned from the REBOOT and BETAMI-DANBLOCK trials]Filippo Ottani, Roberto Latini, Borja Ibanez
European Journal of Heart Failure|December 17, 2019
Dipeptidyl peptidase 3, a biomarker in cardiogenic shock and hopefully much moreAurora Magliocca, Torbjørn Omland, Roberto Latini
Giornale Italiano Di Cardiologia (2006)|December 12, 2022
[Beta-blockers after myocardial infarction with preserved systolic function: useful or redundant?]Filippo Ottani, Lidia Staszewsky, Roberto Latini, et al.
Giornale Italiano Di Cardiologia (2006)|October 8, 2015
[Controversies on the role of mitochondria in coronary reperfusion damage as potential therapeutic target]Roberto Latini, Lidia Staszewsky, Filippo Ottani
Expert Review of Cardiovascular Therapy|March 1, 2016
Heart failure trials on pharmacological therapy in 2015: lessons learned and future outlookRoberto Latini, Serge Masson, Lidia Staszewsky
Pageof 34

Showing results (11-20 of 338) with videos related to

Sort By:
Pageof 34
European Heart Journal|October 24, 2012
What is the atrium trying to tell us?Lidia Staszewsky, Roberto Latini
JACC. Heart Failure|July 11, 2021
In Search of the Lost Ark: Will Troponin Help in Finding Effective Treatments for HFpEF?Roberto Latini, Serge Masson
Methods in Molecular Biology (Clifton, N.J.)|March 5, 2013
Myocardial infarction: cardioprotection by erythropoietinMark I Talan, Roberto Latini
Cardiovascular Drugs and Therapy|September 16, 2004
RAAS inhibitors in the cardiovascular continuum: what is still missing?Aldo P Maggioni, Roberto Latini
Blood Pressure|January 14, 2003
The angiotensin-receptor blockers: from antihypertensives to cardiovascular all-round medications in 10 years?Aldo P Maggioni, Roberto Latini
Giornale Italiano Di Cardiologia (2006)|February 3, 2026
[The paradigm shift for beta-blockers after myocardial infarction. Lessons learned from the REBOOT and BETAMI-DANBLOCK trials]Filippo Ottani, Roberto Latini, Borja Ibanez
European Journal of Heart Failure|December 17, 2019
Dipeptidyl peptidase 3, a biomarker in cardiogenic shock and hopefully much moreAurora Magliocca, Torbjørn Omland, Roberto Latini
Giornale Italiano Di Cardiologia (2006)|December 12, 2022
[Beta-blockers after myocardial infarction with preserved systolic function: useful or redundant?]Filippo Ottani, Lidia Staszewsky, Roberto Latini, et al.
Giornale Italiano Di Cardiologia (2006)|October 8, 2015
[Controversies on the role of mitochondria in coronary reperfusion damage as potential therapeutic target]Roberto Latini, Lidia Staszewsky, Filippo Ottani
Expert Review of Cardiovascular Therapy|March 1, 2016
Heart failure trials on pharmacological therapy in 2015: lessons learned and future outlookRoberto Latini, Serge Masson, Lidia Staszewsky
Pageof 34